Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

711
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
711
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

968
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
968
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

741
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
741
Cancer Survival Analysis01:21

Cancer Survival Analysis

838
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
838
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

1.3K
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
1.3K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

488
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
488

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The choice of time scales in survival analysis has implications: calendar time versus patients' time-to-event.

BMC medical research methodology·2026
Same author

Treatment Dose Increase Versus Co-Medication in Allergic Rhinitis: Systematic Review With Dose-Response Network Meta-Analysis.

Allergy·2026
Same author

Hypomethylating Agents and Venetoclax Based Triplets Targeting FLT3, IDH and KMT2A in Acute Myeloid Leukemia: Current Studies and Challenges of a Tailored Approach.

Cancers·2026
Same author

Producing treatment hierarchies in network meta-analysis using probabilistic models and treatment-choice criteria.

Research synthesis methods·2026
Same author

Trials and triangles: Network meta-analysis of multi-arm trials with correlated arms.

Research synthesis methods·2026
Same author

The Challenge of Time-to-Event Analysis for Multiple Events: A Guided Tour From Time-to-First-Event to Recurrent Time-to-Event Analysis.

Biometrical journal. Biometrische Zeitschrift·2026

Related Experiment Video

Updated: Apr 3, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K

Meta-analysis for aggregated survival data with competing risks: a parametric approach using cumulative incidence

Federico Bonofiglio1,2, Jan Beyersmann3, Martin Schumacher4

  • 1Institute of Medical Biometry and Statistics - Medical Center, University of Freiburg, Freiburg, Germany. bono@imbi.uni-freiburg.de.

Research Synthesis Methods
|September 22, 2015
PubMed
Summary

This study introduces a new meta-analysis method using cumulative incidence function (CIF) ratios to better assess treatment effects on survival when competing risks are present. The approach improves upon traditional hazard ratio (HR) pooling, especially with longer follow-up times.

Keywords:
competing riskscumulative incidence functionmeta-analysisparametric hazard functionrandomized controlled trial

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Related Experiment Videos

Last Updated: Apr 3, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.0K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Area of Science:

  • Biostatistics
  • Clinical Epidemiology
  • Survival Analysis

Background:

  • Meta-analyses commonly pool hazard ratios (HRs) for survival endpoints.
  • Traditional HR pooling can be misleading when competing risks are present, affecting survival probability interpretation.
  • Cumulative incidence functions (CIFs) offer a way to link cause-specific hazards (CSHs) to event probabilities.

Purpose of the Study:

  • To develop and evaluate a meta-analysis method using CIF ratios for assessing treatment effects in the presence of competing risks.
  • To investigate the impact of follow-up duration on pooled cause-specific HRs and CIF ratios.
  • To demonstrate the utility of CIF ratios in revealing treatment effects on cumulative event probabilities.

Main Methods:

  • Proposed a method to pool CIF ratios across studies, assuming constant cause-specific hazards (CSHs) to retrieve aggregated competing risks data.
  • Developed procedures to compute pooled HRs alongside pooled CIF ratios.
  • Assessed the influence of follow-up time on the meta-analysis results.

Main Results:

  • Applied the method to a medical example, demonstrating the relevance of follow-up duration for both pooled CSHRs and CIF ratios.
  • Showed that CIF ratios can provide additional information on treatment effects on cumulative event probabilities, particularly with sufficient all-cause hazard and follow-up time.
  • Highlighted the need for improved reporting of competing risks data in clinical studies.

Conclusions:

  • CIF ratios offer a valuable alternative to HRs for meta-analysis of survival endpoints with competing risks.
  • Follow-up duration significantly influences the interpretation of treatment effects in competing risks meta-analyses.
  • Enhanced reporting of competing risks data is crucial for advancing the reliability and utility of such analyses.